

This listing of the claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (currently amended) Once amended) A method for treating or preventing conditions and diseases associated with IGT or IFG comprising administering a nateglinide or a pharmaceutically acceptable salt thereof to subjects in need thereof
2. (previously presented) The method of claim 1 for the prevention or delay of progression to overt diabetes mellitus type 2; for the prevention, reduction or delay in onset of a condition selected from the group consisting of increased microvascular complications; increased cardiovascular morbidity; excess cerebrovascular diseases; increased cardiovascular mortality and sudden death; higher incidences and mortality rates of malignant neoplasms; and other metabolic disturbances that are associated with IGM.
3. (canceled)
4. (canceled)
5. (previously presented) The method of claim 1 for the treatment of diseases and conditions associated with isolated prandial hyperglycemia and/or IFG.
6. (currently amended) The method of claim 1 for the prevention of conditions or diseases associated with IGT in subjects with prandial glucose excursions having 2 hour plasma glucose values between 7.8 to 11.1 mmol/L after an OGTT or casual glucose test.
7. (canceled)
8. (canceled)
9. (canceled)
10. (withdrawn)
11. (currently amended) The method of claim 5 wherein the diseases and conditions associated with isolated prandial hyperglycemia and/or IFG are selected from the group consisting of obesity, increased age, family history of diabetes, diabetes during pregnancy, dyslipidemia, high blood pressure, uricemia, insulin resistance, arterial occlusive disease, atherosclerosis, retinopathy, nephropathy, angina pectoris, myocardial infarction, and stroke.